Biofrontera Inc. (BFRI) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-3679.1%

-$31.14

vs $0.87 price

Levered DCF

-$41.24

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-6.17

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.55×	-0.34×	-0.21×	-30.07×	-3.41×	-4.66×	-4.88×
P/B	0.55×	1.36×	0.89×	0.81×	11.34×	8.78×	-1.77×
P/S	0.14×	0.16×	0.13×	0.68×	5.34×	2.71×	2.04×
EV / EBITDA	-0.61×	-0.35×	-0.45×	3.77×	-2.83×	-5.77×	-10.36×
Gross margin	78.7%	50.1%	48.8%	47.0%	47.1%	51.9%	52.6%
Operating margin	-21.9%	-46.1%	-66.6%	-64.8%	-104.6%	-51.0%	-57.0%
Net margin	-25.3%	-47.6%	-59.1%	-2.2%	-156.5%	-58.3%	-41.9%
Current ratio	1.52×	1.72×	1.28×	2.06×	3.36×	4.43×	2×
Debt / equity	0.59×	1.11×	1.13×	0.06×	0×	0×	-1.27×
Interest coverage	-20.24×	-8.17×	-37.8×	-50.22×	-70×	-3.32×	-6.91×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-100.5%	-400.6%	-420.0%	-2.7%	-332.6%	-188.5%	36.4%
Return on invested capital	-53.8%	-161.9%	-157.1%	-60.9%	-64.0%	-48.7%	-87.7%
Return on assets	-36.9%	-80.4%	-72.1%	-1.3%	-70.9%	-45.5%	-38.2%
Free cash flow yield	-230.5%	-171.8%	-581.3%	-83.8%	-20.8%	-24.2%	-71.4%
Earnings yield	-181.7%	-295.4%	-470.0%	-3.3%	-29.3%	-21.5%	-20.5%
Enterprise value	$5.6M	$5M	$8.3M	$3.5M	$104.1M	$43.1M	$84.4M
Net debt / EBITDA	0.03×	0.07×	-0.22×	-16.98×	0.67×	1.08×	-3.79×
Cash conversion cycle (days)	46	146	97	236	166	288	145